EQUITY RESEARCH MEMO

Starodub

Generated 5/10/2026

Executive Summary

Conviction (model self-assessment)55/100

Starodub is a Netherlands-based consulting firm established in 2014, specializing in regulatory affairs, quality assurance, and operational improvement for the (bio)pharmaceutical and medical device industries. With a team of 11-50 employees, the company partners with clients to navigate complex regulatory landscapes, ensure GMP compliance, and achieve strategic goals such as market access. Its expertise spans non-clinical development, CMC, regulatory operations, and quality systems for both drugs and medical devices. By offering tailored consulting services, Starodub helps clients streamline product approvals and maintain high quality standards, positioning itself as a critical partner in the life sciences sector. As a private consulting firm, Starodub's growth is closely tied to the evolving regulatory environment and industry demand for compliance expertise. The company's steady niche in regulatory affairs suggests moderate but reliable expansion opportunities. While not a high-growth product company, its specialized services provide a resilient business model with potential for incremental revenue increases through client retention and new engagements. Upcoming catalysts could include new EU regulatory changes, expansion of service lines, or strategic alliances.

Upcoming Catalysts (preview)

  • Q3 2026EU Medical Device Regulation (MDR) Implementation Updates70% success
  • TBDExpansion into Biologics Consulting Services50% success
  • TBDPartnership with Large Pharma for Regulatory Outsourcing40% success
Locked sections
  • · Pipeline Analysis
  • · Competitive Landscape
  • · Catalyst Calendar (full 12-month)
  • · Bull Case
  • · Bear Case
  • · Counterfactual Scenarios
  • · Valuation Notes
  • · SEC Filing Highlights
  • · Insider Activity
  • · Literature Watch
  • · Patent Landscape
  • · Mechanism Cluster Map
  • · Audio Briefing (5 min)